Overview
Annovis Bio Inc (NYSE:ANVS) disclosed a planned underwritten public offering of its common stock together with warrants to purchase common stock, and its shares dropped 24.3% in after-hours trading on Tuesday following the announcement. The company specified that, while the shares and warrants will be issued as separate securities, they will be available for purchase only as a package in the proposed sale.
Offering mechanics and underwriter
Canaccord Genuity has been appointed as the sole bookrunner for the transaction. Annovis cautioned that the offering is contingent on market conditions and other factors. The company explicitly stated there is no guarantee regarding whether or when the offering will be completed, nor any assurance about the ultimate size or terms if it proceeds.
Use of proceeds
The company indicated it intends to apply the net proceeds from the proposed offering toward the ongoing clinical development of its lead investigational oral therapy, buntanetap, in a Phase 3 study for Alzheimer’s disease. Additional uses for the funds were listed as working capital and general corporate purposes.
Pipeline focus
Annovis is developing buntanetap as an oral investigational therapy targeting neurodegenerative illnesses, including Alzheimer’s disease and Parkinson’s disease. The filing frames the offering as a means to support advancement of the Phase 3 program and to provide general corporate liquidity.
Market reaction and uncertainty
Investors reacted to the financing announcement with a sharp after-hours sell-off, reflecting immediate market sensitivity to potential dilution and the open-ended nature of the proposed transaction. The company’s note that the offering is subject to market and other conditions underscores uncertainty about timing and final structure.
This report summarizes the company disclosure regarding the proposed offering and its stated uses of proceeds. It reflects information released by Annovis Bio and the immediate market response noted in after-hours trading.